$ICUI

Voigtlander Christian B. sold $1.6M of ICUI

Voigtlander Christian B. (Chief Operating Officer) sold 8,929 shares of ICU MEDICAL INC/DE (ICUI) at $182.93 ($1.63M total) on 2026-08-11.

Original reporting
SEC EDGAR · Voigtlander Christian B.
Published Aug 11, 2026, 10:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and resulting holdings after the trade. This can influence short-term sentiment but does not change the company’s disclosed fundamentals.

02

Market read

A $1.63M insider sale may draw attention from short-term traders, but it is unlikely to drive a durable repricing without additional company news.

03

What to watch

No 10b5-1 plan is mentioned, but the filing alone does not confirm intent. Traders may want to compare with prior insider activity patterns and total insider ownership changes over time.

Relevance 6/10Novelty 4/10Timing: SEC Form 4 filed on 2026-08-11 (after-hours)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for ICU Medical, Inc.

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical COO Voigtlander sold 8,929 shares in an open-market transaction worth about $1.63M, per an SEC Form 4 filed today.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless accompanied by other company-specific news.

Evidence & confidence

The filing discloses transaction size, price, and post-sale holdings, but provides no new operational, financial, or regulatory information. Insider sales are common and often not predictive without additional context.

Market effects

Minimal. Insider sales in a single medtech name typically do not reset sector expectations without corroborating fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management rather than a negative signal, especially since the article provides no accompanying negative company development.

Key entities

  • ICU Medical, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Voigtlander Christian B.

    Chief Operating Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIMed

ICU Medical rating upgraded by S&P on stronger credit metrics

S&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.

$ICUIMedAI 8/10

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ:ICUI) shares rose 10.2% after the company reported Q2 results that beat Wall Street and lifted full-year guidance. Adjusted EPS was $2.37 vs $1.91 expected, revenue was $551.7 million vs forecasts, and free cash flow improved to $61.64 million. Full-year adjusted EPS guidance was raised to $8.80 (midpoint).

$ICUIHighAI 9/10

ICU Medical (ICUI) Shares Skyrocket, What You Need To Know

ICU Medical (NASDAQ: ICUI) shares rose 10.2% after the company reported Q2 adjusted EPS of $2.37, above the $1.91 consensus, and revenue of $551.7 million, above forecasts. Free cash flow improved to $61.64 million from -$8.49 million a year earlier. ICU Medical raised full-year adjusted earnings guidance to $8.80 per share (midpoint).

$ICUIMedAI 8/10

ICU Medical (NASDAQ:ICUI) Reports Strong Q2 CY2026

ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results. Revenue rose 1.5% year over year to $551.7 million, beating Wall Street’s revenue estimate by 3.5%. Non-GAAP adjusted EPS was $2.37, up from $2.10 and 23.8% above consensus. The stock rose 1.4% to $168.02 after the release.